The country’s conversations on COVID-19 vaccine could have been centred on the locally developed candidate by the African Center of Excellence for Genomics of Infectious Diseases (ACEGID), Osun, rather than relying on Pfizer for early supply.
Lack of funding has driven a wedge between successfu
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
